Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
Key Highlights
- ➤ELPIS II missed its primary RVEF efficacy endpoint at Month 12
- ➤MACE: 8 standard-of-care events versus 1 laromestrocel event, P=0.043
- ➤Longeveron requested FDA meeting to determine HLHS program next steps
- ➤Lucid Capital Markets retained to explore strategic opportunities, including business combination
- ➤Cash $7.2 million expected to fund operations into first quarter 2027
Expert Statements
Stephen H. Willard, Chief Executive Officer of Longeveron
“With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program. At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our stockholders.”
* Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program * The Company has initiated a process to review all strategic options with a goal of maximizing stockholder value and has implemented cash conservation measures to optimize cost containment * Lucid Capital Markets retained as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended September 30, 2026 and provided a business update.
“With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our stockholders.”
Get started
Create a free account to read the full story.